You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFelodipine
Accession NumberDB01023  (APRD00374)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionFelodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.
Structure
Thumb
Synonyms
(+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
Felodipina
Felodipine
Felodipinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Felodipineextended-release Tabletstablet, extended release5 mg/1oralRanbaxy Pharmaceuticals Inc2008-09-10Not applicableUs
Felodipineextended-release Tabletstablet, extended release10 mg/1oralRanbaxy Pharmaceuticals Inc2008-09-10Not applicableUs
Felodipineextended-release Tabletstablet, extended release2.5 mg/1oralRanbaxy Pharmaceuticals Inc2008-09-10Not applicableUs
Plendiltablet, extended release2.5 mg/1oralAstra Zeneca Lp1994-10-04Not applicableUs
Plendiltablet, extended release5 mg/1oralAstra Zeneca Lp1991-09-16Not applicableUs
Plendiltablet, extended release10 mg/1oralAstra Zeneca Lp1991-09-16Not applicableUs
Plendiltablet, extended release10 mg/1oralbryant ranch prepack1991-09-16Not applicableUs
Plendil 10 mgtablet (extended-release)10 mgoralAstrazeneca Canada Inc1992-12-31Not applicableCanada
Plendil 2.5 mgtablet (extended-release)2.5 mgoralAstrazeneca Canada Inc1994-12-31Not applicableCanada
Plendil 5 mgtablet (extended-release)5 mgoralAstrazeneca Canada Inc1992-12-31Not applicableCanada
Renediltablet (extended-release)5 mgoralSanofi Aventis Canada Inc1997-04-212014-06-23Canada
Renediltablet (extended-release)10 mgoralSanofi Aventis Canada Inc1997-05-282014-06-23Canada
Renediltablet (extended-release)2.5 mgoralSanofi Aventis Canada Inc1997-03-242014-06-23Canada
Renedil Srt 10mgtablet (extended-release)10 mgoralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Renedil Srt 10mgtablet (extended-release)10 mgoralHoechst Canada Inc.1992-12-311996-08-29Canada
Renedil Srt 2.5mgtablet (extended-release)2.5 mgoralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Renedil Srt 2.5mgtablet (extended-release)2.5 mgoralHoechst Canada Inc.1994-12-311997-08-05Canada
Renedil Srt 5mgtablet (extended-release)5 mgoralHoechst Roussel Canada Inc.1994-12-311999-08-11Canada
Renedil Srt 5mgtablet (extended-release)5 mgoralHoechst Canada Inc.1992-12-311996-08-29Canada
Sandoz Felodipinetablet (extended-release)10 mgoralSandoz Canada Incorporated2006-08-15Not applicableCanada
Sandoz Felodipinetablet (extended-release)5 mgoralSandoz Canada Incorporated2006-08-15Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-felodipinetablet (extended-release)2.5 mgoralApotex Inc2016-04-22Not applicableCanada
Apo-felodipinetablet (extended-release)5 mgoralApotex Inc2016-04-22Not applicableCanada
Apo-felodipinetablet (extended-release)10 mgoralApotex Inc2016-04-22Not applicableCanada
Felodipinetablet, film coated, extended release5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-16Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralMutual Pharmaceutical Company, Inc.2004-11-02Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralCitron Pharma LLC2013-01-17Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralMylan Pharmaceuticals Inc.2013-03-28Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralAv Kare, Inc.2014-03-312016-01-15Us
Felodipinetablet, film coated, extended release5 mg/1oralPhysicians Total Care, Inc.2005-03-22Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralAurobindo Pharma Limited2013-01-17Not applicableUs
Felodipinetablet, extended release2.5 mg/1oralHeritage Pharmaceuticals Inc.2013-11-08Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralRichmond Pharmaceuticals, Inc.2004-11-02Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralWOCKHARDT USA LLC2010-12-05Not applicableUs
Felodipinetablet, extended release5 mg/1oralQualitest Pharmaceuticals2011-12-15Not applicableUs
Felodipinetablet, extended release5 mg/1oralREMEDYREPACK INC.2011-04-20Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralWockhardt Limited2010-12-05Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-20Not applicableUs
Felodipinetablet, extended release2.5 mg/1oralTorrent Pharmaceuticals Limited2011-11-28Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralMutual Pharmaceutical Company, Inc.2004-11-02Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralbryant ranch prepack2004-11-02Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralPd Rx Pharmaceuticals, Inc.2004-11-02Not applicableUs
Felodipinetablet, extended release5 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralMylan Pharmaceuticals Inc.2013-03-28Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralAv Kare, Inc.2014-03-312016-01-15Us
Felodipinetablet, extended release5 mg/1oralHeritage Pharmaceuticals Inc.2013-11-08Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralRichmond Pharmaceuticals, Inc.2004-11-02Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralWOCKHARDT USA LLC2010-12-05Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralQualitest Pharmaceuticals2011-12-15Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralMylan Institutional Inc.2008-05-01Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralCitron Pharma LLC2013-01-17Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-20Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralMutual Pharmaceutical Company, Inc.2004-11-02Not applicableUs
Felodipinetablet, extended release2.5 mg/1oralbryant ranch prepack2011-11-28Not applicableUs
Felodipinetablet, extended release5 mg/1oralTorrent Pharmaceuticals Limited2011-11-28Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralMylan Pharmaceuticals Inc.2013-03-28Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralMedsource Pharmaceuticals2010-12-20Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralWockhardt Limited2010-12-05Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralCarilion Materials Management2004-11-02Not applicableUs
Felodipinetablet, extended release10 mg/1oralHeritage Pharmaceuticals Inc.2013-11-08Not applicableUs
Felodipinetablet, film coated2.5 mg/1oralPhysicians Total Care, Inc.2005-11-08Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralAurobindo Pharma Limited2013-01-17Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-16Not applicableUs
Felodipinetablet, film coated, extended release10 mg/1oralMylan Institutional Inc.2008-05-01Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralCitron Pharma LLC2013-01-17Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralCarilion Materials Management2010-12-20Not applicableUs
Felodipinetablet, extended release10 mg/1oralTorrent Pharmaceuticals Limited2011-11-28Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralRichmond Pharmaceuticals, Inc.2004-11-02Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralWOCKHARDT USA LLC2010-12-05Not applicableUs
Felodipinetablet, extended release2.5 mg/1oralQualitest Pharmaceuticals2009-03-31Not applicableUs
Felodipinetablet, extended release5 mg/1oralMedsource Pharmaceuticals2011-11-28Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralWockhardt Limited2010-12-05Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralGlenmark Pharmaceuticals Inc., Usa2010-12-20Not applicableUs
Felodipinetablet, film coated, extended release2.5 mg/1oralAv Kare, Inc.2014-03-312016-01-15Us
Felodipinetablet, film coated, extended release10 mg/1oralPhysicians Total Care, Inc.2005-01-21Not applicableUs
Felodipinetablet, film coated, extended release5 mg/1oralAurobindo Pharma Limited2013-01-17Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Felodur ERNot Available
FelogardNot Available
PenedilNot Available
Plendil DepottabAstraZeneca
Plendil ERAstraZeneca
Plendil RetardAstraZeneca
SplendilNot Available
Brand mixtures
NameLabellerIngredients
Altace Plus Felodipine 2.5mg + 2.5mgSanofi Aventis Canada Inc
Altace Plus Felodipine 5mg + 5mgSanofi Aventis Canada Inc
SaltsNot Available
Categories
UNIIOL961R6O2C
CAS number72509-76-3
WeightAverage: 384.254
Monoisotopic: 383.069113515
Chemical FormulaC18H19Cl2NO4
InChI KeyInChIKey=RZTAMFZIAATZDJ-UHFFFAOYSA-N
InChI
InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3
IUPAC Name
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Dihydropyridinecarboxylic acid derivative
  • 1,2-dichlorobenzene
  • Halobenzene
  • Chlorobenzene
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Enamine
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of mild to moderate essential hypertension.
PharmacodynamicsFelodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.
Mechanism of actionFelodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.
Related Articles
AbsorptionIs completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.
Volume of distribution
  • 10 L/kg
Protein binding99%, primarily to the albumin fraction.
Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

SubstrateEnzymesProduct
Felodipine
dehydrofelodipineDetails
Route of eliminationAlthough higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.
Half life17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.
Clearance
  • 0.8 L/min [Young healthy subjects]
ToxicitySymptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD50 is 1050 mg/kg.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Felodipine Action PathwayDrug actionSMP00377
Felodipine Metabolism PathwayDrug metabolismSMP00619
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9878
Blood Brain Barrier-0.83
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.5149
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.8664
CYP450 2C9 substrateNon-substrate0.8357
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6954
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9304
Ames testNon AMES toxic0.7849
CarcinogenicityNon-carcinogens0.7511
BiodegradationNot ready biodegradable0.9527
Rat acute toxicity2.4526 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tablet, film coatedoral2.5 mg/1
Tablet, film coated, extended releaseoral10 mg/1
Tablet, film coated, extended releaseoral2.5 mg/1
Tablet, film coated, extended releaseoral5 mg/1
Tablet, extended releaseoral10 mg/1
Tablet, extended releaseoral2.5 mg/1
Tablet, extended releaseoral5 mg/1
Tablet (extended-release)oral10 mg
Tablet (extended-release)oral2.5 mg
Tablet (extended-release)oral5 mg
Prices
Unit descriptionCostUnit
Plendil 10 mg 24 Hour tablet3.17USD tablet
Plendil er 10 mg tablet3.05USD tablet
Plendil 10 mg tablet sa2.96USD tablet
Felodipine 10 mg 24 Hour tablet2.95USD tablet
Plendil er 2.5 mg tablet2.94USD tablet
Felodipine er 10 mg tablet2.72USD tablet
Plendil er 5 mg tablet2.6USD tablet
Plendil 5 mg 24 Hour tablet1.77USD tablet
Plendil 2.5 mg 24 Hour tablet1.76USD tablet
Felodipine 5 mg 24 Hour tablet1.67USD tablet
Plendil 2.5 mg tablet sa1.65USD tablet
Plendil 5 mg tablet sa1.65USD tablet
Felodipine 2.5 mg 24 Hour tablet1.57USD tablet
Felodipine er 2.5 mg tablet1.51USD tablet
Felodipine er 5 mg tablet1.51USD tablet
Renedil 10 mg Extended-Release Tablet1.22USD tablet
Plendil 10 mg Extended-Release Tablet1.15USD tablet
Renedil 5 mg Extended-Release Tablet0.81USD tablet
Plendil 5 mg Extended-Release Tablet0.77USD tablet
Sandoz Felodipine 10 mg Extended-Release Tablet0.73USD tablet
Renedil 2.5 mg Extended-Release Tablet0.6USD tablet
Plendil 2.5 mg Extended-Release Tablet0.57USD tablet
Sandoz Felodipine 5 mg Extended-Release Tablet0.48USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point145 °CNot Available
water solubility19.7 mg/LNot Available
logP3.86SANGSTER (1994)
Caco2 permeability-4.64ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00715 mg/mLALOGPS
logP4.36ALOGPS
logP3.44ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)5.39ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.63 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity99.2 m3·mol-1ChemAxon
Polarizability38.04 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Vinay Sharma, “Preparation of micron-size felodipine particles by microfluidization.” U.S. Patent US20020086061, issued July 04, 2002.

US20020086061
General References
  1. Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737 ]
External Links
ATC CodesC08CA02C09BB05
AHFS Codes
  • 24:28.08
PDB EntriesNot Available
FDA labelDownload (228 KB)
MSDSDownload (55.4 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Felodipine.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Felodipine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Felodipine.
AcebutololFelodipine may increase the hypotensive activities of Acebutolol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Felodipine.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Felodipine.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Felodipine.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Felodipine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Felodipine.
AlfuzosinAlfuzosin may increase the hypotensive activities of Felodipine.
AliskirenFelodipine may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Felodipine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Felodipine.
AlprenololAlprenolol may increase the hypotensive activities of Felodipine.
AmbrisentanFelodipine may increase the hypotensive activities of Ambrisentan.
AmifostineFelodipine may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Felodipine.
AmiodaroneThe metabolism of Felodipine can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Felodipine.
AmlodipineAmlodipine may increase the hypotensive activities of Felodipine.
AmobarbitalAmobarbital may increase the hypotensive activities of Felodipine.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Felodipine.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Felodipine.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Felodipine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Felodipine.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Felodipine.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Felodipine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Felodipine.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.
AprepitantThe serum concentration of Felodipine can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Felodipine.
AripiprazoleAripiprazole may increase the hypotensive activities of Felodipine.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Felodipine.
AtazanavirThe metabolism of Felodipine can be decreased when combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Felodipine.
AtenololAtenolol may increase the hypotensive activities of Felodipine.
AtomoxetineThe metabolism of Felodipine can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Felodipine.
AtosibanThe risk or severity of adverse effects can be increased when Felodipine is combined with Atosiban.
Atracurium besylateFelodipine may increase the neuromuscular blocking activities of Atracurium besylate.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Felodipine.
AzelastineThe metabolism of Azelastine can be decreased when combined with Felodipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Felodipine.
BarbitalBarbital may increase the hypotensive activities of Felodipine.
BenazeprilBenazepril may increase the hypotensive activities of Felodipine.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Felodipine.
BenmoxinBenmoxin may increase the hypotensive activities of Felodipine.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Felodipine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Felodipine.
BepridilFelodipine may increase the hypotensive activities of Bepridil.
BeraprostThe metabolism of Beraprost can be decreased when combined with Felodipine.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Felodipine.
BetaxololBetaxolol may increase the hypotensive activities of Felodipine.
BethanidineBethanidine may increase the hypotensive activities of Felodipine.
BexaroteneThe serum concentration of Felodipine can be decreased when it is combined with Bexarotene.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Felodipine.
BimatoprostBimatoprost may increase the hypotensive activities of Felodipine.
BisoprololBisoprolol may increase the hypotensive activities of Felodipine.
BoceprevirThe metabolism of Felodipine can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Felodipine.
BortezomibThe metabolism of Felodipine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Felodipine can be decreased when it is combined with Bosentan.
BosentanFelodipine may increase the hypotensive activities of Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Felodipine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.
BretyliumFelodipine may increase the hypotensive activities of Bretylium.
BrimonidineFelodipine may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Felodipine.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Felodipine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Felodipine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.
BupranololFelodipine may increase the hypotensive activities of Bupranolol.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Felodipine.
BupropionThe metabolism of Bupropion can be decreased when combined with Felodipine.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Felodipine.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Felodipine.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Felodipine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Felodipine.
CanagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Felodipine.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Felodipine.
CandoxatrilCandoxatril may increase the hypotensive activities of Felodipine.
CaptoprilFelodipine may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Felodipine can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Felodipine.
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Felodipine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Felodipine.
CaroxazoneCaroxazone may increase the hypotensive activities of Felodipine.
CarteololCarteolol may increase the hypotensive activities of Felodipine.
CarvedilolFelodipine may increase the hypotensive activities of Carvedilol.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Felodipine.
CeliprololFelodipine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Felodipine can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Felodipine.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Felodipine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Felodipine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Felodipine.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Felodipine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Felodipine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Felodipine.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Felodipine.
CilazaprilFelodipine may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine.
CisaprideThe metabolism of Cisapride can be decreased when combined with Felodipine.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Felodipine.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Felodipine.
ClarithromycinThe metabolism of Felodipine can be decreased when combined with Clarithromycin.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Felodipine.
ClemastineThe metabolism of Felodipine can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Felodipine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Felodipine.
ClonidineClonidine may increase the hypotensive activities of Felodipine.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.
ClotrimazoleThe metabolism of Felodipine can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Felodipine.
CobicistatThe metabolism of Felodipine can be decreased when combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Felodipine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Felodipine.
ConivaptanThe serum concentration of Felodipine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Felodipine.
CrizotinibThe metabolism of Felodipine can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Felodipine.
CryptenamineCryptenamine may increase the hypotensive activities of Felodipine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Felodipine.
CyclosporineThe metabolism of Felodipine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Felodipine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Felodipine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Felodipine.
DabrafenibThe serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Felodipine.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Felodipine.
DapagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Felodipine.
DapsoneThe metabolism of Dapsone can be decreased when combined with Felodipine.
DarunavirThe metabolism of Felodipine can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Felodipine.
DasatinibThe serum concentration of Felodipine can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Felodipine.
DebrisoquinFelodipine may increase the hypotensive activities of Debrisoquin.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Felodipine.
DeferasiroxThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Felodipine can be decreased when combined with Delavirdine.
DeserpidineFelodipine may increase the hypotensive activities of Deserpidine.
DexamethasoneThe serum concentration of Felodipine can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Felodipine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Felodipine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Felodipine.
DiazoxideDiazoxide may increase the hypotensive activities of Felodipine.
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Felodipine.
DiclofenamideThe risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Felodipine.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Felodipine.
DihydroergotamineThe metabolism of Felodipine can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Felodipine.
DiltiazemDiltiazem may increase the hypotensive activities of Felodipine.
DinutuximabThe risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Felodipine.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Felodipine.
DorzolamideDorzolamide may increase the hypotensive activities of Felodipine.
DoxazosinDoxazosin may increase the hypotensive activities of Felodipine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Felodipine.
DoxycyclineThe metabolism of Felodipine can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Felodipine can be decreased when combined with Dronedarone.
DuloxetineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Felodipine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Felodipine.
EfavirenzThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Felodipine.
EfonidipineFelodipine may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Felodipine.
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Felodipine.
EmpagliflozinThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Felodipine.
EnalaprilatFelodipine may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.
EnzalutamideThe metabolism of Enzalutamide can be decreased when combined with Felodipine.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Felodipine.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.
EpoprostenolFelodipine may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Felodipine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Felodipine.
ErythromycinThe metabolism of Felodipine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Felodipine.
Eslicarbazepine acetateThe serum concentration of Felodipine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Felodipine.
EstriolThe serum concentration of Estriol can be increased when it is combined with Felodipine.
EstroneThe serum concentration of Estrone can be increased when it is combined with Felodipine.
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Felodipine.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Felodipine.
EtravirineThe serum concentration of Felodipine can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Felodipine.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Felodipine.
FenoldopamFenoldopam may increase the hypotensive activities of Felodipine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Felodipine.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Felodipine.
FluconazoleThe serum concentration of Felodipine can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Felodipine.
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Felodipine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Felodipine.
FluvoxamineThe metabolism of Felodipine can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Felodipine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Felodipine.
FosphenytoinThe metabolism of Felodipine can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Felodipine.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.
Fusidic AcidThe serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Felodipine.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Felodipine.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Felodipine.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Felodipine.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Felodipine.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Felodipine.
GuanabenzGuanabenz may increase the hypotensive activities of Felodipine.
GuanadrelGuanadrel may increase the hypotensive activities of Felodipine.
GuanethidineFelodipine may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may increase the hypotensive activities of Felodipine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Felodipine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Felodipine.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Felodipine.
HexamethoniumFelodipine may increase the hypotensive activities of Hexamethonium.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Felodipine.
HexobarbitalHexobarbital may increase the hypotensive activities of Felodipine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Felodipine.
HydralazineFelodipine may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Felodipine.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Felodipine.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Felodipine.
IdelalisibThe serum concentration of Felodipine can be increased when it is combined with Idelalisib.
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Felodipine.
IloprostIloprost may increase the hypotensive activities of Felodipine.
ImatinibThe metabolism of Felodipine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Felodipine.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Felodipine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Felodipine.
IndapamideIndapamide may increase the hypotensive activities of Felodipine.
IndenololFelodipine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Felodipine can be decreased when combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Felodipine.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Felodipine.
IndoraminFelodipine may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Felodipine.
IproniazidIproniazid may increase the hypotensive activities of Felodipine.
IrbesartanFelodipine may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Felodipine.
IsavuconazoniumThe metabolism of Felodipine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Felodipine.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Felodipine.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.
IsoxsuprineThe risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Felodipine.
ItraconazoleThe serum concentration of Felodipine can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Felodipine can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Felodipine.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Felodipine.
KetamineThe metabolism of Ketamine can be decreased when combined with Felodipine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Felodipine.
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Felodipine.
KetoconazoleThe serum concentration of Felodipine can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Felodipine.
LacidipineFelodipine may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Felodipine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Felodipine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Felodipine.
LapatinibThe metabolism of Lapatinib can be decreased when combined with Felodipine.
LatanoprostLatanoprost may increase the hypotensive activities of Felodipine.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Felodipine.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Felodipine.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Felodipine.
LercanidipineLercanidipine may increase the hypotensive activities of Felodipine.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Felodipine.
LevobunololThe risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.
LevodopaFelodipine may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Felodipine.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.
LicofeloneThe metabolism of Licofelone can be decreased when combined with Felodipine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Felodipine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Felodipine.
LisinoprilLisinopril may increase the hypotensive activities of Felodipine.
LofexidineFelodipine may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Felodipine.
LopinavirThe metabolism of Felodipine can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Felodipine.
LosartanLosartan may increase the hypotensive activities of Felodipine.
LovastatinThe metabolism of Felodipine can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Felodipine can be increased when it is combined with Luliconazole.
MacitentanFelodipine may increase the hypotensive activities of Macitentan.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium hydroxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Sulfate.
ManidipineFelodipine may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.
MebanazineMebanazine may increase the hypotensive activities of Felodipine.
MecamylamineMecamylamine may increase the hypotensive activities of Felodipine.
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Felodipine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Felodipine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Felodipine.
MethadoneThe metabolism of Methadone can be decreased when combined with Felodipine.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.
MethohexitalMethohexital may increase the hypotensive activities of Felodipine.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Felodipine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.
MethyldopaMethyldopa may increase the hypotensive activities of Felodipine.
Methylene blueMethylene blue may increase the hypotensive activities of Felodipine.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Felodipine.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Felodipine.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.
MetipranololFelodipine may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Felodipine.
MetoprololMetoprolol may increase the hypotensive activities of Felodipine.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Felodipine.
MibefradilFelodipine may increase the hypotensive activities of Mibefradil.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Felodipine.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Felodipine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Felodipine.
MifepristoneThe metabolism of Felodipine can be decreased when combined with Mifepristone.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Felodipine.
MinaprineMinaprine may increase the hypotensive activities of Felodipine.
MinoxidilMinoxidil may increase the hypotensive activities of Felodipine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Felodipine.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Felodipine.
MitotaneThe serum concentration of Felodipine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Felodipine.
MivacuriumFelodipine may increase the neuromuscular blocking activities of Mivacurium.
MoclobemideMoclobemide may increase the hypotensive activities of Felodipine.
ModafinilThe serum concentration of Felodipine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Felodipine.
MolsidomineMolsidomine may increase the hypotensive activities of Felodipine.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Felodipine.
MorphineThe serum concentration of Morphine can be increased when it is combined with Felodipine.
MoxonidineFelodipine may increase the hypotensive activities of Moxonidine.
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Felodipine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Felodipine.
NadololFelodipine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Felodipine can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Felodipine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Felodipine.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Felodipine.
NaproxenThe metabolism of Naproxen can be decreased when combined with Felodipine.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Felodipine.
NebivololFelodipine may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Felodipine can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Felodipine can be decreased when combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Felodipine.
NesiritideThe risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.
NetupitantThe serum concentration of Felodipine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Felodipine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Felodipine.
NicardipineNicardipine may increase the hypotensive activities of Felodipine.
NicorandilNicorandil may increase the hypotensive activities of Felodipine.
NicotineThe metabolism of Nicotine can be decreased when combined with Felodipine.
NifedipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.
NiguldipineFelodipine may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Felodipine can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Felodipine.
NilvadipineFelodipine may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Felodipine.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Felodipine.
NisoldipineNisoldipine may increase the hypotensive activities of Felodipine.
NitrendipineFelodipine may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.
NitroprussideFelodipine may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Felodipine.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Felodipine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Felodipine.
ObinutuzumabFelodipine may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Felodipine.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Felodipine.
OlaparibThe metabolism of Felodipine can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Felodipine.
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Felodipine.
OmapatrilatOmapatrilat may increase the hypotensive activities of Felodipine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Felodipine.
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Felodipine.
OsimertinibThe serum concentration of Felodipine can be increased when it is combined with Osimertinib.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Felodipine.
OxprenololFelodipine may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Felodipine.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Felodipine.
PalbociclibThe serum concentration of Felodipine can be increased when it is combined with Palbociclib.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Felodipine.
PapaverineThe risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Felodipine.
PargylineFelodipine may increase the hypotensive activities of Pargyline.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.
PenbutololFelodipine may increase the hypotensive activities of Penbutolol.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Felodipine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Felodipine.
PentobarbitalPentobarbital may increase the hypotensive activities of Felodipine.
PentoliniumFelodipine may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Felodipine.
PerindoprilPerindopril may increase the hypotensive activities of Felodipine.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Felodipine.
PhenelzinePhenelzine may increase the hypotensive activities of Felodipine.
PheniprazinePheniprazine may increase the hypotensive activities of Felodipine.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Felodipine.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Felodipine.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Felodipine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Felodipine.
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Felodipine.
PhentolaminePhentolamine may increase the hypotensive activities of Felodipine.
PhenytoinThe metabolism of Felodipine can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Felodipine.
PinacidilFelodipine may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Felodipine.
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Felodipine.
PirlindolePirlindole may increase the hypotensive activities of Felodipine.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Felodipine.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Felodipine.
PivhydrazinePivhydrazine may increase the hypotensive activities of Felodipine.
PolythiazideFelodipine may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Felodipine.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Felodipine.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Felodipine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Felodipine.
PrazosinPrazosin may increase the hypotensive activities of Felodipine.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Felodipine.
PrimidonePrimidone may increase the hypotensive activities of Felodipine.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Felodipine.
PropofolThe metabolism of Propofol can be decreased when combined with Felodipine.
PropranololPropranolol may increase the hypotensive activities of Felodipine.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Felodipine.
QuetiapineThe risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.
QuinaprilQuinapril may increase the hypotensive activities of Felodipine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Felodipine.
QuinineQuinine may increase the hypotensive activities of Felodipine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Felodipine.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Felodipine.
RamiprilRamipril may increase the hypotensive activities of Felodipine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Felodipine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Felodipine.
RanolazineThe metabolism of Felodipine can be decreased when combined with Ranolazine.
RapacuroniumFelodipine may increase the neuromuscular blocking activities of Rapacuronium.
RasagilineRasagiline may increase the hypotensive activities of Felodipine.
RemikirenRemikiren may increase the hypotensive activities of Felodipine.
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Felodipine.
RescinnamineFelodipine may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Felodipine.
RifabutinThe metabolism of Felodipine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Felodipine can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Felodipine.
RifapentineThe metabolism of Felodipine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Felodipine.
RiociguatFelodipine may increase the hypotensive activities of Riociguat.
RisperidoneFelodipine may increase the hypotensive activities of Risperidone.
RitonavirThe metabolism of Felodipine can be decreased when combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Felodipine.
RituximabFelodipine may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Felodipine.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Felodipine.
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Felodipine.
SafrazineSafrazine may increase the hypotensive activities of Felodipine.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Felodipine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Felodipine.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Felodipine.
SaprisartanFelodipine may increase the hypotensive activities of Saprisartan.
SaquinavirThe metabolism of Felodipine can be decreased when combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Felodipine.
SecobarbitalSecobarbital may increase the hypotensive activities of Felodipine.
SelegilineSelegiline may increase the hypotensive activities of Felodipine.
SelegilineThe metabolism of Selegiline can be decreased when combined with Felodipine.
SelexipagFelodipine may increase the hypotensive activities of Selexipag.
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Felodipine.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Felodipine.
SildenafilSildenafil may increase the antihypertensive activities of Felodipine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Felodipine.
SilodosinSilodosin may increase the hypotensive activities of Felodipine.
SiltuximabThe serum concentration of Felodipine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Felodipine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Felodipine.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Felodipine.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Felodipine.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Felodipine.
SitaxentanFelodipine may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Felodipine.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Felodipine.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Felodipine.
SpiraprilFelodipine may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.
St. John's WortThe serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Felodipine can be increased when it is combined with Stiripentol.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Felodipine.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Felodipine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Felodipine.
SulfisoxazoleThe metabolism of Felodipine can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Felodipine.
TadalafilTadalafil may increase the antihypertensive activities of Felodipine.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Felodipine.
TamsulosinTamsulosin may increase the hypotensive activities of Felodipine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Felodipine.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Felodipine.
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Felodipine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Felodipine.
TelaprevirThe metabolism of Felodipine can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Felodipine.
TelithromycinThe metabolism of Felodipine can be decreased when combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Felodipine.
TemazepamThe metabolism of Temazepam can be decreased when combined with Felodipine.
TemocaprilFelodipine may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Felodipine.
TerazosinTerazosin may increase the hypotensive activities of Felodipine.
TerazosinThe risk or severity of adverse effects can be increased when Felodipine is combined with Terazosin.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Felodipine.
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Felodipine.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Felodipine.
TerlipressinFelodipine may increase the hypotensive activities of Terlipressin.
TestosteroneThe metabolism of Testosterone can be decreased when combined with Felodipine.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Felodipine.
ThiamylalThiamylal may increase the hypotensive activities of Felodipine.
ThiopentalThiopental may increase the hypotensive activities of Felodipine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Felodipine.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Felodipine.
TiboloneFelodipine may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Felodipine.
TiclopidineThe metabolism of Felodipine can be decreased when combined with Ticlopidine.
TicrynafenFelodipine may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Felodipine.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Felodipine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.
TocilizumabThe serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.
TolazolineTolazoline may increase the hypotensive activities of Felodipine.
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Felodipine.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Felodipine.
ToloxatoneToloxatone may increase the hypotensive activities of Felodipine.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Felodipine.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Felodipine.
TorasemideTorasemide may increase the hypotensive activities of Felodipine.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Felodipine.
TrandolaprilTrandolapril may increase the hypotensive activities of Felodipine.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Felodipine.
TranylcypromineTranylcypromine may increase the hypotensive activities of Felodipine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Felodipine.
TravoprostTravoprost may increase the hypotensive activities of Felodipine.
TreprostinilTreprostinil may increase the hypotensive activities of Felodipine.
TretinoinThe metabolism of Tretinoin can be decreased when combined with Felodipine.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Felodipine.
TrimazosinFelodipine may increase the hypotensive activities of Trimazosin.
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Felodipine.
TrimethaphanFelodipine may increase the hypotensive activities of Trimethaphan.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Felodipine.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Felodipine.
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Felodipine.
UdenafilUdenafil may increase the antihypertensive activities of Felodipine.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Felodipine.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Felodipine.
UnoprostoneFelodipine may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Felodipine.
VardenafilVardenafil may increase the antihypertensive activities of Felodipine.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Felodipine.
VenlafaxineThe metabolism of Felodipine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Felodipine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Felodipine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Felodipine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Felodipine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Felodipine.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Felodipine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Felodipine.
WarfarinThe metabolism of Warfarin can be decreased when combined with Felodipine.
XylometazolineFelodipine may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Felodipine.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Felodipine.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Felodipine.
ZiprasidoneThe metabolism of Felodipine can be decreased when combined with Ziprasidone.
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Felodipine.
Food Interactions
  • Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903 ]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-contraction coupling (By similarity).
Gene Name:
CACNA2D1
Uniprot ID:
P54289
Molecular Weight:
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903 ]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting.
Gene Name:
CACNB2
Uniprot ID:
Q08289
Molecular Weight:
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73. [PubMed:10525060 ]
  3. Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2. [PubMed:17475903 ]
  4. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Titin binding
Specific Function:
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number of protein kinases and phosphatases. Together with CCP110 and centrin, is involved in a genetic pathway that regulates the centrosome cycle and progression through cytokinesis.
Gene Name:
CALM1
Uniprot ID:
P62158
Molecular Weight:
16837.47 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884 ]
  2. Johnson JD, Andrews CT, Khabbaza EJ, Mills JS: The interaction of felodipine with calcium-binding proteins. J Cardiovasc Pharmacol. 1987;10 Suppl 1:S53-9. [PubMed:2442519 ]
  3. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  4. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559 ]
  5. Mills JS, Bailey BL, Johnson JD: Cooperativity among calmodulin's drug binding sites. Biochemistry. 1985 Aug 27;24(18):4897-902. [PubMed:4074665 ]
  6. Walsh MP, Sutherland C, Scott-Woo GC: Effects of felodipine (a dihydropyridine calcium channel blocker) and analogues on calmodulin-dependent enzymes. Biochem Pharmacol. 1988 Apr 15;37(8):1569-80. [PubMed:2833901 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as a substrate.
Gene Name:
PDE1B
Uniprot ID:
Q01064
Molecular Weight:
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cGMP than for cAMP.
Gene Name:
PDE1A
Uniprot ID:
P54750
Molecular Weight:
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041 ]
  2. Sharma RK, Wang JH, Wu Z: Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists. J Neurochem. 1997 Aug;69(2):845-50. [PubMed:9231746 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension. 2008 Mar;51(3):742-8. doi: 10.1161/HYPERTENSIONAHA.107.103580. Epub 2008 Feb 4. [PubMed:18250364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Calcium ion binding
Specific Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
Gene Name:
TNNC2
Uniprot ID:
P02585
Molecular Weight:
18121.895 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884 ]
  2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Troponin t binding
Specific Function:
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site for tropomyosin and Tn-C. The binding of calcium to Tn-C abolishes the inhibitory action of Tn on actin filaments.
Gene Name:
TNNC1
Uniprot ID:
P63316
Molecular Weight:
18402.36 Da
References
  1. Bostrom SL, Westerlund C, Rochester S, Vogel HJ: Binding of a dihydropyridine felodipine-analogue to calmodulin and related calcium-binding proteins. Biochem Pharmacol. 1988 Oct 1;37(19):3723-8. [PubMed:3178884 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22. [PubMed:12433827 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF: Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem. 2008 Jun 20;283(25):17227-37. doi: 10.1074/jbc.M802180200. Epub 2008 Apr 15. [PubMed:18413310 ]
  2. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23